Compare Abeona Therapeutics Inc (ABEO) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vital Farms Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Vital Farms Inc trades at $11.45 (market cap $496.50M). The key difference: Vital Farms Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | VITL | |
|---|---|---|
Market Cap | $421.19M | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $52.41 |
52-Week Low | $4.17 | $8.28 |
Enterprise Value | $276.10M | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Vital Farms (VITL) trades at $11.52, up 2.31% today, amid bearish technical signals and challenging fundamentals. The stock shows oversold conditions with RSI at 29.21, while recent Q2 2026 results revealed a $0.47 per share loss despite beating revenue estimates. The company secured $125 million in financing to navigate industry oversupply pressures and elevated costs affecting profitability.
While analyst consensus remains positive with a $13.00 price target and no sell ratings, near-term headwinds from margin compression and net cash outflows pose significant risks. The stock's valuation appears reasonable with P/E of 11.77 and P/S of 0.67, but investors should monitor execution on cost management and revenue stabilization for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
